These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 36797664)

  • 1. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
    Cameron D; Kumar Sharma V; Biswas C; Clarke C; Chandiwana D; Pathak P
    J Med Econ; 2023; 26(1):357-365. PubMed ID: 36797664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole
    Jhaveri K; O'Shaughnessy J; Fasching PA; Tolaney SM; Yardley DA; Sharma VK; Biswas C; Thuerigen A; Pathak P; Rugo HS
    Ther Adv Med Oncol; 2023; 15():17588359231216095. PubMed ID: 38107828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom.
    Suri G; Chandiwana D; Lee A; Mistry R
    J Health Econ Outcomes Res; 2019; 6(2):20-31. PubMed ID: 32685577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of ribociclib plus letrozole
    Buehler AM; Castilho G; Dionne PA; Stefani S
    Ther Adv Med Oncol; 2021; 13():17588359211000593. PubMed ID: 33948121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
    Stellato D; Thabane ME; Park J; Chandiwana D; Delea TE
    Pharmacoeconomics; 2021 Sep; 39(9):1045-1058. PubMed ID: 34105083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
    Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
    Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
    Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model.
    Darvishi A; Daroudi R; Fazaeli AA
    Health Econ Rev; 2023 Nov; 13(1):53. PubMed ID: 37943359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain.
    Galve-Calvo E; González-Haba E; Gostkorzewicz J; Martínez I; Pérez-Mitru A
    Clinicoecon Outcomes Res; 2018; 10():773-790. PubMed ID: 30532569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2- breast cancer in Mexico.
    Molina-Jaimes M; Galindo-González A; Verduzco-Aguirre HC; Bautista-Arredondo S; Reyes-Terán G; Soto-Perez-de-Celis E
    Clin Transl Oncol; 2024 Jan; 26(1):239-244. PubMed ID: 37329428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Mistry R; Suri G; Young K; Hettle R; May JR; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya D; Bhattacharyya S; Mishra D; Dalal AA
    Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
    Berrios K; Burum A; Jeong E; Zhong L
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
    Stellato D; Thabane ME; Chandiwana D; Park J; Delea TE
    Pharmacoeconomics; 2021 Jul; 39(7):853-867. PubMed ID: 34002341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
    Neven P; Fasching PA; Chia S; Jerusalem G; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Zarate JP; Wang Y; Chakravartty A; Wang C; Slamon DJ
    Breast Cancer Res; 2023 Aug; 25(1):103. PubMed ID: 37653397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    Zhang B; Long EF
    Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
    Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
    Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer.
    Fasching PA; Delea TE; Lu YS; De Boer R; Hurvitz SA; Moynahan A; Chandiwana D; Lanoue B; Hu H; Thuerigen A; O'Shaughnessy J
    Cancer Manag Res; 2021; 13():8179-8189. PubMed ID: 34754238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.